Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference
October 23 2019 - 8:30AM
Atossa Genetics Inc. (NASDAQ:
ATOS), a
clinical-stage biopharmaceutical company developing novel
therapeutics and delivery methods for breast cancer and other
breast conditions, today announced that Kyle Guse, CFO and General
Counsel of Atossa Genetics will be a featured presenter at the 5th
Annual Dawson James Small Cap Growth Conference on October 29, 2019
at 11:20 AM Eastern Time. The conference is being held at the
Wyndham Grand Hotel in Jupiter, Florida.
Mr. Guse will provide an overview of the Company’s business
model and growth strategy and will be available for one-on-one
meetings. Interested investors may request a meeting time by
contacting conference coordinator Karen Payne at
kpayne@symposiaevents.com.
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage biopharmaceutical
company developing novel therapeutics and delivery methods to treat
breast cancer and other breast conditions. For more information,
please visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between
preliminary and final clinical results, actions and inactions by
the FDA, the outcome or timing of regulatory approvals needed by
Atossa including those needed to commence studies, lower than
anticipated rate of patient enrollment, estimated market size of
drugs under development, the safety and efficacy of Atossa's
products and services, performance of clinical research
organizations and investigators, obstacles resulting from
proprietary rights held by others with respect to fulvestrant, such
as patent rights, potential market sizes for Atossa's drugs under
development and other risks detailed from time to time in Atossa's
filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each
as amended and supplemented from time to time.
Atossa Genetics Company Contact:Atossa
Genetics, Inc.Kyle GuseCFO and General CounselOffice: 206
556-3238kyle.guse@atossagenetics.com
Investor Relations Contact:Scott
GordonCoreIR377 Oak StreetConcourse 2Garden City, NY 11530Office:
516.222.2560scottg@CoreIR.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Sep 2023 to Sep 2024